- The Cure from CRISPR Classroom
- Preventing AML Relapse with Cell Engineering
Preventing AML Relapse with Cell Engineering
PLUS: First Patient Dosed in Parkinson’s Stem Cell Trial
Hi friends 👋🏼,
The Cure was launched on March 12, 2023, and hit 400 subscribers this week! 🥳 If you enjoy it, please share us with your colleagues, friends, and communities.
Here’s what we’ll break down this week:
Preventing AML Relapse with Cell Engineering READER REQUEST
First Patient Dosed in Parkinson’s Stem Cell Trial
Targeting Integrins in Primary Sclerosing Cholangitis READER REQUEST
Duchenne Muscular Dystrophy Trial Begins Recruitment READER REQUEST
🩸Preventing AML Relapse with Cell Engineering
Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow, causing an overproduction of abnormal blood cells that can lead to infection, anemia, bleeding, and, eventually, death.
1/ Current treatment of AML usually consists of chemotherapy followed by a hematopoietic stem cell transplant (HSCT) to “clean out” cancerous cells from the bone marrow.
2/ After stem cell transplantation, patients can no longer receive targeted cancer therapies since those same therapies would be toxic to the fragile and newly transplanted cells. As a result, around 40% of patients who receive a stem cell transplant relapse, and less than 20% survive another two years.
3/ Vor Bio is developing a novel approach to help stop this relapse by engineering hematopoietic stem cells in a way that allows for follow-up targeted cancer therapies.
How Vor Bio’s cell therapy works 👇🏼
Subscribe to The Cure to read the rest.
Become a paying subscriber of The Cure to get access to this post and other subscriber-only content.
Already a paying subscriber? Sign In